Sildenafil on Improving Chronic Lung Disease of neonates

Study of the Effect of Sildenafil on Improving Chronic Lung Disease of neonates

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160102025811N4

Enrollment

Registered

2020-04-17

Start date

2018-07-23

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic lung disease of newborns. Newborn (suspected to be) affected by other maternal circulatory and respiratory diseases

Interventions

Intervention 1: Intervention group: Sildenafil 50 mg tablets from Obidi Company with a dose of 2 mg per kg body weight will be fed to infants every 8 hours. Intervention 2: Control group: The placebo

Eligibility

Sex/Gender

All

Age

No minimum to 28 Days

Inclusion criteria

Inclusion criteria: Chronic pulmonary disease based on oxygen demand in 36 weeks of intrauterine age Infant hemodynamic stability Absence of gastrointestinal disorders Written consent of the patient's parents to participate in the study

Exclusion criteria

Exclusion criteria: Parents 'dissatisfaction with patients' participation in the study The need for oxygen during the 36 weeks of intrauterine age is known due to chronic lung disease Hemodynamic instability Nutritional intolerance

Design outcomes

Primary

Measure	Time frame
Fio2. Timepoint: daily. Method of measurement: Oxymetric pulse and heart monitoring.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMirHadi Mousavi

Tabriz University of Medical Sciences

mirhadimousavi33@yahoo.com+98 41 3526 2255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026